If this was confirmed, then FGF-21 agonists could be potentially introduced as an add-on to DAAs in specific subsets of patients, in whom the metabolic risk associated with liver steatosis remains elevated regardless of viral eradication. This evidence concerns the gene FGF21 and Hepatic steatosis.